02:05 PM EDT, 10/17/2024 (MT Newswires) -- Amylyx Pharmaceuticals ( AMLX ) shares jumped 9% in recent trading Thursday after the company said AMX0035 was found to benefit Wolfram syndrome patients in a phase 2 clinical trial.

Results showed that subjects with Wolfram syndrome had an improvement in pancreatic function after 24 weeks of treatment as measured by a marker known as C-peptide response.

Participants also saw improvements across other, secondary health markers, such as glycemic control and vision, the company said.

Wolfram syndrome is a rare genetic disorder that affects multiple systems in the body, leading to diabetes and other complications from an early age.

Amylyx said it plans to meet with the US Food and Drug Administration to discuss a phase 3 program and expects to provide an update next year.

Price: 4.45, Change: +0.37, Percent Change: +8.95